Aldurazyme (Biomarin Pharmaceuticals)
Aldurazyme (Biomarin Pharmaceuticals) Brand names, Aldurazyme (Biomarin Pharmaceuticals) Analogs
Aldurazyme (Biomarin Pharmaceuticals) Brand Names Mixture
- No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) Chemical_Formula
C3160H4848N898O881S12
Aldurazyme (Biomarin Pharmaceuticals) RX_link
http://www.rxlist.com/cgi/generic3/aldurazyme.htm
Aldurazyme (Biomarin Pharmaceuticals) fda sheet
Aldurazyme (Biomarin Pharmaceuticals) msds (material safety sheet)
Aldurazyme (Biomarin Pharmaceuticals) Synthesis Reference
No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) Molecular Weight
69899.4
Aldurazyme (Biomarin Pharmaceuticals) Melting Point
Mandelli J, Wajner A, Pires R, Giugliani R, Coelho JC. Detection of mucopolysaccharidosis type I heterozygotes on the basis of the biochemical properties of plasma alpha-L-iduronidase. Clin Chim Acta. 2001 Oct;312(1-2):81-6.
Aldurazyme (Biomarin Pharmaceuticals) H2O Solubility
No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) State
Liquid
Aldurazyme (Biomarin Pharmaceuticals) LogP
-0.300
Aldurazyme (Biomarin Pharmaceuticals) Dosage Forms
Solution (IV infusion)
Aldurazyme (Biomarin Pharmaceuticals) Indication
For the treatment of mucopolysaccharidosis
Aldurazyme (Biomarin Pharmaceuticals) Pharmacology
Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.
Aldurazyme (Biomarin Pharmaceuticals) Absorption
No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) side effects and Toxicity
No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) Patient Information
No information avaliable
Aldurazyme (Biomarin Pharmaceuticals) Organisms Affected
Humans and other mammals
